Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by Blue Trust Inc.

Blue Trust Inc. grew its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 7.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,023 shares of the medical research company’s stock after acquiring an additional 146 shares during the period. Blue Trust Inc.’s holdings in Charles River Laboratories International were worth $398,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Flagship Harbor Advisors LLC acquired a new stake in Charles River Laboratories International during the 4th quarter valued at approximately $237,000. Veracity Capital LLC acquired a new stake in shares of Charles River Laboratories International during the fourth quarter worth approximately $589,000. Mitchell & Pahl Private Wealth LLC increased its stake in shares of Charles River Laboratories International by 8.8% in the fourth quarter. Mitchell & Pahl Private Wealth LLC now owns 3,603 shares of the medical research company’s stock worth $665,000 after buying an additional 292 shares during the last quarter. Kera Capital Partners Inc. acquired a new stake in Charles River Laboratories International in the fourth quarter valued at $246,000. Finally, Pinnacle Bancorp Inc. boosted its stake in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 65 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CRL has been the topic of a number of recent analyst reports. Bank of America reduced their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. CLSA downgraded Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target for the company. in a report on Monday, November 18th. StockNews.com downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. The Goldman Sachs Group reduced their price target on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. Finally, Evercore ISI boosted their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. Three research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $204.38.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $164.88 on Friday. The stock has a market cap of $8.43 billion, a P/E ratio of 20.64, a P/E/G ratio of 6.13 and a beta of 1.38. The firm’s 50-day simple moving average is $184.15 and its 200 day simple moving average is $195.67. Charles River Laboratories International, Inc. has a fifty-two week low of $159.65 and a fifty-two week high of $275.00. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. During the same period in the prior year, the business posted $2.72 EPS. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. Equities analysts expect that Charles River Laboratories International, Inc. will post 10.17 EPS for the current year.

Insider Activity at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).